Researchers sought to evaluate differences in ctDNA profiles, use of targeted treatments, and overall survival between Black and White patients with metastatic breast cancer.

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...

Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat cancer.

Microcystic LMs are a rare, chronically debilitating genetic disease caused by dysregulation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. The disease is ...

Here are a couple of promising candidates in the PI3K/AKT/mTOR inhibitor category. In January 2025, Eli Lilly announced plans to acquire Scorpion Therapeutics’ experimental cancer therapy, STX-478, ...

Deregulation of the Phosphoinositide 3-kinase (PI3K) pathway is associated with metabolic flexibility leading to cancer poor prognosis. Here, the authors show that targeting both glutamine ...

Figure 1. Summary of key findings from each study featured in this editorial, highlighting diverse therapeutic strategies targeting kinase activity and signaling pathways. (a) dual inhibition of MEK ...

The PI3K/AKT/mTOR (PAM) signaling pathway is a classical pathway that is aberrantly activated in cancer cells and promotes the tumorigenesis, metastasis, resistance to castration therapy, ...